Coloplast A/S COLO-B.CO
Nasdaq Copenhagen · Healthcare · Medical Instruments & Supplies
508.20 DKK
−3.3%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Coloplast
| DKK million | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 19,426 | 22,579 | 24,500 | 27,030 |
| EBITDA | 7,050 | 7,229 | 7,732 | 8,480 |
| Net income | 4,825 | 4,706 | 4,783 | 5,052 |
| Balance sheet | ||||
| Equity | 8,168 | 8,292 | 17,299 | 17,942 |
| Total debt | 2,786 | 18,708 | 19,567 | 22,629 |
| Cash | 448 | 414 | 911 | 788 |
| Net debt | 2,338 | 18,294 | 18,656 | 21,841 |
| Ratios and per share | ||||
| EBITDA margin | 36.3% | 32.0% | 31.6% | 31.4% |
| Profit margin | 24.8% | 20.8% | 19.5% | 18.7% |
| Return on equity | 59.1% | 56.8% | 27.6% | 28.2% |
| Earnings/share (DKK) | 22.67 | 22.17 | 21.29 | 22.42 |
| Book value/share (DKK) | 38.38 | 39.06 | 77.00 | 79.62 |
| Shares outstanding (M) | 213 | 212 | 225 | 225 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | – |
| EV / EBITDA | – |
| Net debt / EBITDA | – |
| Return on equity | – |
| Profit margin | – |
| Beta 1Y | 0.44 |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2026 | 5.00 |
| 2025 | 23.00 |
| 2024 | 22.00 |
| 2023 | 21.00 |
| 2022 | 20.00 |
| 2021 | 14.00 |
Not investment advice. Figures may contain errors from the data source.